/ /

  • linkedin
  • Increase Font
  • Sharebar

    FDA responds to Avedro NDA


    Waltham, MA—Avedro Inc. has received a complete response letter from the FDA regarding the new drug application (NDA) for its riboflavin ophthalmic solution/KXL System.

    Additionally, in the response letter, the agency identified several areas of the application that require additional information.

    “We plan on working closely with the FDA to resolve these issues as quickly as possible to make this important treatment available to patients in the United States,” said David Muller, PhD, chief executive officer of Avedro. “While we do not yet have an estimate on how long it will take to resolve the issues, we are confident that we can adequately answer their questions.

    “However, we continue to grow internationally by bringing advanced corneal cross-linking (CXL) procedures to ophthalmologists and patients around the world. This expansion also includes the development and refinement of our (technology) for photorefractive intrastromal CXL,” Dr. Muller continued.


    For more articles in this issue of Ophthalmology Times eReport, click here.



    To receive weekly clinical news and updates in ophthalmology, subscribe to the Ophthalmology Times eReport.

    Rose Schneider Krivich
    Rose is the content specialist for Medical Economics.

    New Call-to-action


    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available


    View Results